New contact lenses that deliver allergy medication for itchy eyes
Official title: Drug delivery platform for ocular allergy therapy
Funded at Lynthera Corporation · NIH-10922084 · Data updated 2026-11-12
This study is testing a new type of contact lens that releases allergy medicine directly to your eyes, making it easier and more comfortable for people with itchy eyes from allergies to find relief without using eye drops all the time.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lynthera Corporation NIH-funded |
| Lab location | 1 site (Lancaster, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $900,003 |
| NIH project number | 2R44EY033611-02 |
| Project ID | NIH-10922084 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who wear contact lenses and experience symptoms of allergic conjunctivitis.
✕Less likely to help
Patients who do not wear contact lenses or do not suffer from allergic conjunctivitis may not benefit from this research.
What this research studies
This research focuses on developing a next-generation contact lens that delivers the allergy medication olopatadine directly to the eyes. It aims to improve the comfort and effectiveness of allergy treatment for contact lens wearers who suffer from itchy eyes due to allergic conjunctivitis. The approach involves using innovative drug delivery technology to control the release of the medication, enhancing its efficacy while maintaining lens breathability. Patients will benefit from a more convenient and effective way to manage their allergy symptoms without the need for frequent eye drops.
Why it matters
Potential benefit: If successful, this research could provide a more effective and convenient treatment option for patients suffering from ocular allergies.
How similar studies have gone: Other research has shown success with similar drug delivery approaches in contact lenses, indicating a promising avenue for allergy treatment.
Where this research is happening
-
Lynthera Corporation
Lancaster, United States Active
Researchers
- Principal investigator: Yang, Arthur — Lynthera Corporation
- Study coordinator: Yang, Arthur
Related research
Other NIH-funded projects on the same topics.
-
New Horizons in preventing and treating food allergy
A Johns Hopkins-led effort aims to advance how we prevent and treat food allergies across all ages by coordinating high-quality studies and developing better therapies.
-
Understanding antibiotic allergy to improve care for patients
Scientists are testing new ideas to understand why some people develop severe allergic reactions to antibiotics and how to prevent or treat them.
-
Antibiotic Allergy: Types, Triggers, and How they Work
This grant aims to better understand why certain antibiotics trigger immediate allergic reactions and how to improve testing and diagnosis for patients with suspected antibiotic allergies.
-
Understanding alpha-gal meat allergy and how the body's immune system reacts
This grant studies why some people develop a dangerous allergy to meat due to a molecule called alpha-gal and how it triggers life-threatening reactions.
-
New Horizons in Food Allergy Prevention and Treatment
A large, multi-site program at Johns Hopkins aims to advance prevention and treatment of food allergies across all ages.
-
Food allergy outcomes by race/ethnicity from infancy through adolescence
This study follows children with food allergies over time to understand how race and ethnicity relate to allergy management, outcomes, and quality of life.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.